Antibodies.com is a leading supplier of protein research tools. Discover more with our range of distinct antibodies, proteins, kits, and other reagents.
|Telephone:||+ 44 (0)1223 298 875|
|Address:||129 Town Street, Newton|
|Membership type:||Professional Individual and Corporate < 5 (£50+VAT pa)|
Antibodies.com is a private company founded by scientists and dedicated to providing the best in class research and diagnostic reagents. Headquartered in Cambridge (UK), with a logistics hub in San Jose (USA), we serve life scientists worldwide – helping accelerate our understanding of biology and facilitate personalised medicine.
We can support your research with high-quality & characterised protein research tools, expert customer service, fast global delivery, and accurate product specifications.
Our growing product range caters for every discipline and includes; primary & secondary antibodies, proteins & peptides, immunoassays & kits, and other companion products.
- 50,000+ distinct & validated protein research tools.
- Extensive datasheets: images, citations, and reviews.
- 24-hour response to all enquiries.
- Order online or by email, phone, or fax.
- 100+ countries delivered to.
To find out more, please visit Antibodies.com.
Antibodies are widely used in pre-clinical research to study proteins and their functions in biological pathways and diseased states. Antibodies.com has incorporated knockout validation (using CRISPR/Cas9), the most accepted method for validating antibody specificity, as part of its standard antibody validation process.
3 October 2018Read in full
CEO appointment marks a step change in growth strategy as Antibodies.com aims to become a market-leading global supplier of life science research tools.
7 September 2018Read in full
Antibodies.com has been selected by the Southern Universities Purchasing Consortium (SUPC) as a preferred supplier of research antibodies for the United Kingdom (UK) Higher Education Sector - under Lot 1 of the Inter-Regional Laboratory Agreement for Antibodies & Sera (IRLA).
9 February 2017Read in full